Repository logo
 
Publication

PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice

2021-10Journal article Open access
Simple item page
dc.contributor.authorFerreira, Abigail
dc.contributor.authorMartins, Helena
dc.contributor.authorOliveira, José Carlos
dc.contributor.authorLapa, Rui
dc.contributor.authorVale, Nuno
dc.date.accessioned2024-01-30T12:27:34Z
dc.date.available2024-01-30T12:27:34Z
dc.date.issued2021-10
dc.description.abstractThe importance of closely observing patients receiving antibiotic therapy, performing therapeutic drug monitoring (TDM), and regularly adjusting dosing regimens has been extensively demonstrated. Additionally, antibiotic resistance is a contemporary concerningly dangerous issue. Optimizing the use of antibiotics is crucial to ensure treatment efficacy and prevent toxicity caused by overdosing, as well as to combat the prevalence and wide spread of resistant strains. Some antibiotics have been selected and reserved for the treatment of severe infections, including amikacin, gentamicin, tobramycin, and vancomycin. Critically ill patients often require long treatments, hospitalization, and require particular attention regarding TDM and dosing adjustments. As these antibiotics are eliminated by the kidneys, critical deterioration of renal function and toxic effects must be prevented. In this work, clinical data from a Portuguese cohort of 82 inpatients was analyzed and physiologically based pharmacokinetic (PBPK) modeling and simulation was used to study the influence of different therapeutic regimens and parameters as biological sex, body weight, and renal function on the biodistribution and pharmacokinetic (PK) profile of these four antibiotics. Renal function demonstrated the greatest impact on plasma concentration of these antibiotics, and vancomycin had the most considerable accumulation in plasma over time, particularly in patients with impaired renal function. Thus, through a PBPK study, it is possible to understand which pharmacokinetic parameters will have the greatest variation in a given population receiving antibiotic administrations in hospital context.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFerreira A, Martins H, Oliveira JC, Lapa R, Vale N. PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice. Life (Basel). 2021;11(11):1130. doi:10.3390/life11111130pt_PT
dc.identifier.doi10.3390/life11111130pt_PT
dc.identifier.issn2075-1729
dc.identifier.urihttp://hdl.handle.net/10400.16/2906
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationNew advance in biomedicine: peptide-mediated target drug delivery
dc.relationAssociated Laboratory for Green Chemistry - Clean Technologies and Processes
dc.relation.publisherversionhttps://www.mdpi.com/2075-1729/11/11/1130pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectGastroPlus™pt_PT
dc.subjectPBPK modelingpt_PT
dc.subjectamikacinpt_PT
dc.subjectantibiotics usept_PT
dc.subjectgentamicinpt_PT
dc.subjecttherapeutic drug monitoringpt_PT
dc.subjecttobramycinpt_PT
dc.subjectvancomycinpt_PT
dc.titlePBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practicept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleNew advance in biomedicine: peptide-mediated target drug delivery
oaire.awardTitleAssociated Laboratory for Green Chemistry - Clean Technologies and Processes
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/Investigador FCT/IF%2F00092%2F2014%2FCP1255%2FCT0004/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID%2FQUI%2F50006%2F2019/PT
oaire.citation.conferencePlaceSwitzerlandpt_PT
oaire.citation.issue11pt_PT
oaire.citation.startPage1130pt_PT
oaire.citation.titleLifept_PT
oaire.citation.volume11pt_PT
oaire.fundingStreamInvestigador FCT
oaire.fundingStream6817 - DCRRNI ID
person.familyNameOliveira
person.givenNameJosé Carlos
person.identifier806053
person.identifier.ciencia-id801F-D4FE-8694
person.identifier.orcid0000-0003-2142-6839
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationbd6d8008-2622-4368-8ded-4ec1c1160c82
relation.isAuthorOfPublication.latestForDiscoverybd6d8008-2622-4368-8ded-4ec1c1160c82
relation.isProjectOfPublication3740b032-4740-4984-adba-d2b6e2c2eeec
relation.isProjectOfPublication459a4212-8b10-42bb-abb1-64830129c446
relation.isProjectOfPublication.latestForDiscovery3740b032-4740-4984-adba-d2b6e2c2eeec

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ferreira-2021-Pbpk-modeling-and-simulation-of-ant.pdf
Size:
2.57 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

SQC - Artigos publicados em revistas indexadas na Pubmed/Medline